BioCentury | Jul 11, 2016
Financial News

Bone Medical completes private placement

Bone Medical Ltd. (ASX:BNE), West Perth, Australia Business: Musculoskeletal, Autoimmune Date completed: 2016-06-27 Type: Private placement Raised: A$3.5 million ($2.6 million) Shares: 175 million Price: A$0.02 Shares after offering: 405.4 million WIR Staff autoimmune Musculoskeletal...
BioCentury | Aug 22, 2011
Emerging Company Profile

Tarsa: Fishing in a big pond

...through the epithelial cells of the intestine, which can reduce the compound's bioavailability, Brand said. Bone Medical Ltd....
...in the solubility of the solid-dose formulation in the intestine. Brand would not comment on Bone Medical's...
...the product expire in 2025. Companies and Institutions Mentioned Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Bone Medical Ltd....
BioCentury | Jun 23, 2008
Company News

Bone Medical, Hyundai Pharmaceutical Co. Ltd. deal

...granted Hyundai an exclusive license to commercialize CaPTHymone in South Korea. Bone Medical retains rights elsewhere. Bone Medical...
...hormone is in Phase I/II testing to treat osteoporosis. Further deal terms were not disclosed. Bone Medical Ltd....
BioCentury | May 26, 2008
Clinical News

Capsitonin: Phase III start

...By year end, Bone Medical will begin a Phase III trial to compare oral Capsitonin given once...
...III trial to compare oral Capsitonin given once daily with an intranasal formulation of calcitonin. Bone Medical Ltd....
BioCentury | May 19, 2008
Clinical News

CaPTHymone: Additional Phase I/II data

...for Forteo teriparatide from Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) (see BioCentury, Feb. 11). Bone Medical Ltd....
BioCentury | Feb 11, 2008
Clinical News

CaPTHymone: Phase I/II data

...Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.), is approved to treat osteoporosis in post-menopausal women. Bone Medical Ltd....
BioCentury | Feb 4, 2008
Clinical News

Bone Medical preclinical data

...secretion of tumor necrosis factor (TNF) by macrophage-type cells. The compound is a TNF regulator. Bone Medical Ltd....
BioCentury | Dec 3, 2007
Clinical News

CaPTHymone: Phase I/II started

...in 8 healthy post-menopausal women to compare 400 and 800 µg doses of oral CaPTHymone. Bone Medical Ltd....
BioCentury | Sep 17, 2007
Company News

Bone Medical board of directors update

Bone Medical Ltd. (ASX:BNE), Como, Australia Business: Musculoskeletal, Autoimmune Appointed: Leif Helth Jensen, formerly a director at DentoFit A/S Resigned: Gabriel Chiappini WIR Staff...
BioCentury | Aug 27, 2007
Clinical News

Perthoxal: Phase I/IIa start

...in 8 healthy post-menopausal women to compare 400 and 800 µg doses of oral Perthoxal. Bone Medical Ltd....
Items per page:
1 - 10 of 22
BioCentury | Jul 11, 2016
Financial News

Bone Medical completes private placement

Bone Medical Ltd. (ASX:BNE), West Perth, Australia Business: Musculoskeletal, Autoimmune Date completed: 2016-06-27 Type: Private placement Raised: A$3.5 million ($2.6 million) Shares: 175 million Price: A$0.02 Shares after offering: 405.4 million WIR Staff autoimmune Musculoskeletal...
BioCentury | Aug 22, 2011
Emerging Company Profile

Tarsa: Fishing in a big pond

...through the epithelial cells of the intestine, which can reduce the compound's bioavailability, Brand said. Bone Medical Ltd....
...in the solubility of the solid-dose formulation in the intestine. Brand would not comment on Bone Medical's...
...the product expire in 2025. Companies and Institutions Mentioned Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Bone Medical Ltd....
BioCentury | Jun 23, 2008
Company News

Bone Medical, Hyundai Pharmaceutical Co. Ltd. deal

...granted Hyundai an exclusive license to commercialize CaPTHymone in South Korea. Bone Medical retains rights elsewhere. Bone Medical...
...hormone is in Phase I/II testing to treat osteoporosis. Further deal terms were not disclosed. Bone Medical Ltd....
BioCentury | May 26, 2008
Clinical News

Capsitonin: Phase III start

...By year end, Bone Medical will begin a Phase III trial to compare oral Capsitonin given once...
...III trial to compare oral Capsitonin given once daily with an intranasal formulation of calcitonin. Bone Medical Ltd....
BioCentury | May 19, 2008
Clinical News

CaPTHymone: Additional Phase I/II data

...for Forteo teriparatide from Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) (see BioCentury, Feb. 11). Bone Medical Ltd....
BioCentury | Feb 11, 2008
Clinical News

CaPTHymone: Phase I/II data

...Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.), is approved to treat osteoporosis in post-menopausal women. Bone Medical Ltd....
BioCentury | Feb 4, 2008
Clinical News

Bone Medical preclinical data

...secretion of tumor necrosis factor (TNF) by macrophage-type cells. The compound is a TNF regulator. Bone Medical Ltd....
BioCentury | Dec 3, 2007
Clinical News

CaPTHymone: Phase I/II started

...in 8 healthy post-menopausal women to compare 400 and 800 µg doses of oral CaPTHymone. Bone Medical Ltd....
BioCentury | Sep 17, 2007
Company News

Bone Medical board of directors update

Bone Medical Ltd. (ASX:BNE), Como, Australia Business: Musculoskeletal, Autoimmune Appointed: Leif Helth Jensen, formerly a director at DentoFit A/S Resigned: Gabriel Chiappini WIR Staff...
BioCentury | Aug 27, 2007
Clinical News

Perthoxal: Phase I/IIa start

...in 8 healthy post-menopausal women to compare 400 and 800 µg doses of oral Perthoxal. Bone Medical Ltd....
Items per page:
1 - 10 of 22